ACTRN12617000982314已完成1 期
Phase I, Double-Blind, Randomized Study of Daily, Twice-Weekly and Once-Weekly APL 2 in Healthy Volunteers
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 55 Years（—）
- 性别
- All
入选标准
- •Medically healthy adults
- •Weigh more than 49 kg and less than 91 kg and have a BMI higher than 18.4 kg/m2 and lower than 32.1 kg/m2.
- •Have been vaccinated against Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenza within two years or willing to receive vaccinations.
排除标准
- •Mentally or legally incapacitated or has significant emotional problems or has a history of a significant medical or psychiatric condition or a history of hypersensitivity to compounds related to APL-2 or a history of chronic infections or a recent active infection or recent surgery.
- •Use of any prescription or non-prescription medications, herbal remedies, or vitamin supplements within the last 14 days
- •Blood donation or significant blood loss within previous 56 days or plasma donation within previous 7 days
- •Participation in another clinical trial within the previous 28 days
- •Female subjects who are pregnant or lactating
研究者
相似试验
招募中
1 期
A study to determine the safety, tolerability and ability to provoke an immune response of graded doses of the STX-100/Alhydrogel vaccine in healthy volunteersACTRN12617001027303Clinical Network Services (CNS) Pty Ltd20
已完成
2 期
An Early Phase-II, Randomized, Double-blind, Study of TAS5315 in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexaterheumatoid arthritisJPRN-jRCT2080223962Taiho Pharmaceutical Co., Ltd.90
已完成
不适用
Study of egg-derived influenza vaccine and cell culture-derived influenza vaccine in healthy adult volunteersDiseases of the blood and blood -forming organs and certain disorders involving the immune mechanismKCT0001240SK Chemicals100
已完成
1 期
A placebo and comparator controlled phase 1, safety and tolerability study of 3 ascending doses of INP105 (intranasal OLZ by I231 POD® device).Acute Agitation in SchizophreniaAcute Agitation in Bipolar I DisorderNeurological - Other neurological disordersMental Health - SchizophreniaACTRN12618000966291Clinical Network Services (CNS) Pty Ltd40
已完成
不适用
A Phase 1, Randomized, Double-Blind, Placebo- and Positive-Controlled, Parallel-Group Study to Evaluate the Effect of LMTM on the Response to an Oral Tyramine Challenge and to Determine the Multiple-Dose Pharmacokinetics of LMTM.Alzheimers Diseasethinking and behaviortype of dementia that affects memory10042258NL-OMON51826TauRx Therapeutics Ltd.120